The Royal Victoria Regional Health Centre (formerly the Royal Victoria Hospital) is an Advanced Level II facility with stroke designation, serving the needs of the population of the City of Barrie and the surrounding area. The facility is located at 201 Georgian Drive in Barrie, Ontario, Canada. The CEO is Janice Skot. As of 2017, the hospital operated on a $340 million annual budget.The Royal Victoria Regional Health Centre is a 299-bed acute care facility. With a team of over 380 physicians, 2,500 staff members and 850 volunteers, the RVH provides healthcare specializing in cancer care, surgical services, critical care, mental health rehabilitation services, as well as women and children's programs.The Royal Victoria Regional Health Centre is the only hospital in Barrie and is the regional hospital for a large geographical region including central Simcoe County Barrie, Innisfil (Alcona, Stroud, Gilford), Springwater (Elmvale, Midhurst, Minesing, Snow Valley), south Oro- Medonte (Horseshoe Valley, Shanty Bay), a small portion of Essa Township (Ivy, Thornton).The hospital dates to 1891, when it was known as the "Barrie General Hospital", which was located on Duckworth Street near Ardagh's Grove. The facility has relocated and expanded many times since its inception.
Introduction: Front-line therapy with Azacitidine (AZA) + Venetoclax (Ven) improved overall survival (OS) and remissions in acute myeloid leukemia (AML) patients ineligible for standard induction. Less is known about the outcome of AML treated with AZA + Ven in the "real world". Methods: We assessed the comparative pattern of administration, tolerability, efficacy and safety of AZA vs. AZA + Ven administered at our cancer centre. We retrospectively reviewed all patients treated with AZA alone or AZA + Ven. Patients who received less than one cycle or proceeded with consolidative stem cell transplant were excluded. Results: A total of 53 patients, median age 77 years, received AZA, and 23 patients, median age 73 years, received AZA + Ven. Among those, 69% and 47.8% were ≥75 years old, respectively. Only 52% received Ven doses above 200 mg. Mean time on therapy was 13.1 months in AZA vs. 5.9 months in AZA + Ven. Treatment delays occurred in 22.6% of AZA and 34.8% of AZA + Ven patients, primarily due to infections and cytopenias. Neutropenia grade 3/4 occurred in 28.3% of AZA vs. 56.5% of AZA + Ven patients. Thrombocytopenia grade 3/4 occurred in 15.1% of AZA and 51.2% of AZA + Ven patients. Anemia grade 3/4 occurred in 5.7% of AZA vs. 30.4% of AZA + Ven patients. Moreover, 69.8% of AZA and 69.5% AZA + Ven patients reached stable disease/partial and complete remission. Median overall survival (OS) was similar: 18 months in AZA vs. 14 months in the AZA + Ven group, p = 0.905. Conclusions: In a community setting, the addition of Venetoclax to AZA did not improve overall survival or disease control, mainly due to low tolerability and higher toxicity. However, these results should be interpreted cautiously due to a significant imbalance in the cytogenetic risk profiles and lower tolerability in the combined group. This suggests the need for a larger study with adjusted analyses.
OBJECTIVE:The Canadian Wound Program Information, Services, and Evaluation (CAN-WISE) questionnaire was developed to assess and evaluate acute wound care programs across Canada, addressing variations in service accessibility and program effectiveness. METHODS:An expert panel of 9 acute care wound management program leads reviewed and assessed the CAN-WISE questionnaire. Content Validity Ratios (CVR), Scale Content Validity Index (S-CVI), Modified Kappa, Gwet's AC1, and Brennan-Prediger tests were utilized to evaluate the relevance and reliability of both questions and responses. Percentage agreement metrics were also used to assess the clarity and vocabulary of the questions and responses. RESULTS:The results of this validation study demonstrated high consensus among the expert panel for the final questionnaire, with question CVRs ranging from 0.777 to 1, elevated I-CVI scores of 0.888 to 1, and high, statistically relevant inter-rater reliability scores (AC1=0.966, Brennan-Prediger=0.934), demonstrating that the questions included were both essential and well constructed. Questionnaire responses demonstrated similarly high CVR scores (0.777 to 1), I-CVI scores (0.888 to 1), and statistically relevant reliability (AC1=0.988, Brennan-Prediger=0.976). Clarity and vocabulary analysis showed high absolute agreement levels of 95.88% and 98.96%, respectively. These reliability metrics were further supported by high, statistically relevant Gwet's AC1 and Brennan-Prediger test results for clarity and vocabulary, confirming the tool's comprehensibility. CONCLUSIONS:The CAN-WISE questionnaire has demonstrated validity and reliability in its ability to evaluate acute care wound management programs in Canada. It provides a valuable tool for assessing program strengths and areas for improvement to improve acute wound care programs throughout the nation.
Patient-specific quality assurance (PSQA) is an essential component of modern radiotherapy, ensuring safe and accurate delivery of increasingly complex treatments. Given its resource-intensive nature and the availability of evolving approaches, examining how PSQA is implemented and optimized across Canada is important to inform best practices. This study aimed to characterize the current landscape of PSQA practice across Canadian radiotherapy centers, identify patterns and regional variations, and explore opportunities for future national guidance. A 30-question web-based survey was developed and distributed in March 2024 to all Canadian radiotherapy centers, including satellites. The survey addressed staffing, treatment machines, PSQA tools and methodologies, policies, data analysis, frequency of PSQA, and failure management. Responses were collected in both English and French, de-identified, and analyzed by center size and region (British Columbia, Prairies, Ontario, Quebec, and Atlantic). The survey achieved a 90% response rate (45 of 50 centers). Most centers reported using 3D array detectors, followed by EPID and point detectors. Gamma index analysis was the predominant evaluation method. More than half of participating centers, including 65% of large centers, reported reducing PSQA measurement frequency, citing accumulated local experience rather than external guidance. However, all centers in the Prairies and Atlantic regions reported maintaining full measurement frequency. A vast majority of centers that used delivery log calculations also reported a reduction in measurement frequency, while most centers using EPID did not. Across all regions, selective adoption of recommendations from both Canadian and American guidelines was observed. PSQA practices in Canada are heterogeneous, reflecting local resources, institutional experience, and evolving international recommendations. Given the resource-intensive nature of PSQA and observed variability in practice, these findings highlight the value of developing national guidance tailored to Canadian clinical realities.
OBJECTIVES:We performed a retrospective study comparing 2 rectal preparation regimens, Polyethylene Glycol 3350 (PEG) and Fleet Enema (FE), in patients undergoing prostate stereotactic body radiation therapy (SBRT). METHODS:The study included 24 patients receiving prostate SBRT (40 Gy in 5 fractions), for a total of 120 treatment fractions. Patients received either FE (N = 73) or PEG (N = 47) for rectal preparation. Outcomes included: (1) treatment time, measured from the initial setup cone-beam CT (CBCT) to the post-treatment CBCT (including rectal-related interventions, excluding machine delays); (2) intra-fraction motion, defined as the displacement vector between verification and post-treatment CBCTs registered to fiducial markers; and (3) clinical acceptability, determined by blinded review of all setup CBCTs by 3 radiation therapists (RTs), who scored each scan as either "Acceptable" (proceed directly to treatment) or "Need Intervention." Regression analysis was used to compare regimens. RESULTS:Population-averaged median treatment times were 14 minutes (95% CI, 5.8-22.2) for PEG and 11 minutes (95% CI, 9.6-12.3) for FE, with greater time variability in PEG (P < .001). Intra-fraction motion did not differ significantly between regimens. All 3 RTs judged the setup CBCTs as clinically acceptable for treatment 47.7% of the time (95% CI, 31.6%-63.8%) for the PEG regimen and 74.4% of the time (95% CI, 61%-87.8%) for the FE regimen. CONCLUSIONS:Overall, the FE regimen showed greater consistency in all outcome measures. This suggests an operational advantage for using FE since it results in more consistent patient treatment times without negatively impacting treatment quality and precision. ADVANCES IN KNOWLEDGE:Daily FE improves the consistency of prostate SBRT treatment and enhances the clinical workflow by minimizing unplanned disruptions.